LIVE
📈 Stocks 📊 Neutral 🌍 United States

MiniMed Reports 16% Organic Revenue Growth in First Independent Quarter

MiniMed delivered 16% organic growth in Q1 2027, driven by the successful U.S. rollout of the MiniMed Flex pump and expanded international sensor availability, signaling strong momentum for the newly independent firm.

🕐 1 min read
#DiabetesCare #earnings #Medtech #MiniMed
Impact
10/10

💡 Key Takeaways

  • Organic revenue growth reached 16%, exceeding internal expectations and accelerating from the previous quarter.
  • The MiniMed Flex pump launch drove a 20% year-over-year increase in new U.S. pump sales.
  • New prescriber base expanded by 24% as the company successfully targeted MDI patients.
  • International markets saw double-digit growth, supported by a 3x increase in Simplera sensor supply.

📋 Executive Summary

MiniMed posted a strong start to fiscal year 2027, reporting 16% organic revenue growth in its first full quarter as an independent public company. The performance was bolstered by the successful U.S. launch of the MiniMed Flex insulin pump and increased international sensor supply, with management noting that new prescriber numbers rose 24% year-over-year.

📊 Sentiment Analysis

Sentiment
📊 Neutral
Impact Score
10/10
Region
🌍 United States
Asset Class
📈 Stocks

❓ Frequently Asked Questions

📰 Source

📅 Originally published:
🔗 View Original Article

⚠️ Disclaimer: This content is for training purposes only and should not be considered financial advice. Always conduct your own research before making investment decisions.